Ask AI
ProCE Banner Series

The HER2 Horizon: The Next Era of HER2 Targeted Treatment in GI Cancer

Join us for this interactive, live CME/EBAC-certified webinar featuring expert perspectives on HER2 testing and the use of HER2-targeted therapy for advanced biliary tract and gastroesophageal cancers, with a focus on recent practice-changing studies. Be sure to bring your questions for the live Q&A session with the expert panel.  

  AMA
Who Should Attend

This activity is intended for medical oncologists and other healthcare professionals involved in the care of patients with gastroesophageal adenocarcinoma and biliary tract cancer.

All Events

The HER2 Horizon: The Next Era of HER2 Targeted Treatment in GI Cancer

Upcoming Events

August

27

2026

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Topics

Gastrointestinal Cancers 

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and confidence in applying biomarker-driven, evidence-based, and patient-centered HER2-directed treatment strategies for patients with gastroesophageal adenocarcinoma and biliary tract cancer.

Target Audience
This activity is intended for medical oncologists and other healthcare professionals involved in the care of patients with gastroesophageal adenocarcinoma and biliary tract cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply guideline-concordant HER2 testing and interpretation strategies for GEA and BTC, including appropriate integration of pathology results with PD-L1 status and broader molecular profiling

  • Critically evaluate newly presented and recently reported clinical trial data in HER2-positive GEA and BTC, distinguishing established standards from investigational approaches

  • Individualize treatment selection and sequencing for patients with HER2-positive GEA and BTC based on disease setting, prior therapy, biomarker profile, comorbidities, toxicity risk, and patient goals

  • Implement proactive monitoring and mitigation strategies for clinically relevant toxicities associated with HER2-directed therapies

  • Identify appropriate patients for referral to clinical trials evaluating novel HER2-directed agents and combinations in GI malignancies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC Accreditation 

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/65f35ab16f6ca.png

Clinical Care Options, LLC dba Decera Clinical Education is an EBAC® accredited provider since 2025 

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.0 hour of effective education time. 

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively. 

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™. 

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA), the World Federation for Medical Education (WFME) CPD Recognition Committee, and a partner member of the International Association of Medical Regulatory Authorities (IAMRA). 

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191